Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.33 |
| ▸ | POLQ | O75417 | 3/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19320901 | 0.91 | TP53 (0.39) | RIPK1SIGMAR1TMEM97ADRA1ATP53 | |
| SCHEMBL19325551 | 0.90 | CACNA1G (0.35) | CACNA1GCACNA1HCACNA1IRIPK1SIGMAR1 | |
| SCHEMBL19320900 | 0.86 | HCAR2 (0.39) | RIPK1SIGMAR1TMEM97ADRA1APRMT5 | |
| SCHEMBL19320898 | 0.83 | RIPK1 (0.42) | CACNA1GCACNA1HCACNA1IRIPK1SIGMAR1 | |
| SCHEMBL19325964 | 0.83 | TP53 (0.38) | RIPK1SIGMAR1TMEM97TP53 | |
| SCHEMBL19325960 | 0.77 | HCAR2 (0.39) | RIPK1SIGMAR1TMEM97ADRA1A | |
| SCHEMBL19320896 | 0.76 | CACNA1G (0.42) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL19320827 | 0.74 | CYP3A4 (0.32) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL19325528 | 0.74 | RIPK1 (0.41) | CACNA1GCACNA1HCACNA1IRIPK1SIGMAR1 | |
| SCHEMBL18366104 | 0.72 | POLB (0.54) | CACNA1GCACNA1HCACNA1IRIPK1POLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | CPN1, HAT1, PRSS1 | CACNA1G 3034/4885CACNA1H 2888/4885CACNA1I 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.